Nanoparticle technology for treatment of Parkinson’s disease: The role of surface phenomena in reaching the brain

Renal clearance of quantum dots

Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476 · see citing works

Epidemiology of Parkinson's disease

de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110 · see citing works

Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art

Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759 · see citing works

Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles

OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637 · see citing works

Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives

Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · see citing works

Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles

Cedervall, T., Lynch, I., Lindman, S., Berggård, T., Thulin, E., Nilsson, H., Dawson, K. A., & Linse, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608582104 · Cited by 3,281 · see citing works

Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts

Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 3,037 · see citing works

Nanoparticle PEGylation for Imaging and Therapy

Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,054 · see citing works

Physical−Chemical Aspects of Protein Corona: Relevance to<i>in Vitro</i>and<i>in Vivo</i>Biological Impacts of Nanoparticles

Monopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, F., & Dawson, K. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107583h · Cited by 1,835 · see citing works

Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment

Walkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758 · see citing works

Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity

Eeden, S. K. V. D. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,746 · see citing works

Encyclopedia of pharmaceutical technology

(2003) · Choice Reviews Online · doi:10.5860/choice.40-6157 · Cited by 1,741 · see citing works

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

Chaudhuri, К. R., & Schapira, A. H. V. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,739 · see citing works

‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption

Gref, R., Lück, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T., & Müller, R. H. (2000) · Colloids and Surfaces B Biointerfaces · doi:10.1016/s0927-7765(99)00156-3 · Cited by 1,725 · see citing works

Freeze-drying of nanoparticles: Formulation, process and storage considerations

ABDELWAHED, W., DEGOBERT, G., STAINMESSE, S., & FESSI, H. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.017 · Cited by 1,611 · see citing works

Pharmacological Treatment of Parkinson Disease

Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,510 · see citing works

Interpretation of Protein Adsorption: Surface-Induced Conformational Changes

Roach, P., Farrar, D. F., & Perry, C. C. (2005) · Journal of the American Chemical Society · doi:10.1021/ja042898o · Cited by 1,487 · see citing works

Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles

Reis, C. P., Neufeld, R. J., Ribeiro, A. J., & Veiga, F. (2006) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2005.12.003 · Cited by 1,355 · see citing works

Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.

Abuchowski, A., McCoy, J. R., Palczuk, N. C., Es, T. V., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,276 · see citing works

Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties

Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,228 · see citing works

Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation

KECK, C., & MULLER, R. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.05.009 · Cited by 1,061 · see citing works

Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution

Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., & McNeil, S. E. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800032f · Cited by 1,022 · see citing works

Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation

Deng, Z. J., Liang, M., Monteiro, M. J., Tóth, I., & Minchin, R. F. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2010.250 · Cited by 893 · see citing works

Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases

Gabathuler, R. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 804 · see citing works

Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability

Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of drug targeting · doi:10.1080/10611860400015936 · Cited by 742 · see citing works

Parameters influencing the stealthiness of colloidal drug delivery systems

Vonarbourg, A., Passirani, C., Saulnier, P., & Benoit, J.-P. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.03.039 · Cited by 740 · see citing works

The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage

Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721 · see citing works

Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions

Freitas, C., & Müller, R. H. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00092-1 · Cited by 689 · see citing works

Immune activation in brain aging and neurodegeneration: too much or too little?

Lucin, K. M., & Wyss-Coray, T. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.039 · Cited by 679 · see citing works

<i>In vivo</i> diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space

Thorne, R. G., & Nicholson, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509425103 · Cited by 641 · see citing works

Potential of solid lipid nanoparticles in brain targeting.

Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615 · see citing works

Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB)

Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591 · see citing works

Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes

Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.005 · Cited by 558 · see citing works

Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?

Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554 · see citing works

Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)

Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., & Aa, I. (1995) · Brain Research · doi:10.1016/0006-8993(95)00023-j · Cited by 538 · see citing works

Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes

Ishida, T., & Kiwada, H. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.11.005 · Cited by 496 · see citing works

Priorities in Parkinson's disease research

Meissner, W. G., Frasier, M. A., Gasser, T., Goetz, C. G., Lozano, A. M., Piccini, P. P., Obeso, J. A., Rascol, O., Schapira, A. H. V., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 439 · see citing works

Drug delivery to the central nervous system: a review.

Misra, A. R., Ganesh, S. D., Shahiwala, A., & Shah, S. P. (2003) · PubMed · Cited by 434 · see citing works

Parkinson's Disease in a Chemist Working with 1-Methyl-4-Phenyl-L,2,5,6-Tetrahydropyridine

Langston, J. W., & Ballard, P. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308043090511 · Cited by 406 · see citing works

A Coarse-Grained Model for Polyethylene Oxide and Polyethylene Glycol: Conformation and Hydrodynamics

Lee, H., de Vries, A. H., Marrink, ‪. J., & Pastor, R. W. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp9058966 · Cited by 400 · see citing works

Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease

Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., & Kumar, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032616 · Cited by 399 · see citing works

Drug delivery to the central nervous system: A review

Tamargo, R. J., & Brem, H. (1992) · Neurosurgery Quarterly · Cited by 370 · see citing works

Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes

Ishida, T., Harada, M., Wang, X., Ichihara, M., Irimura, K., & Kiwada, H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.04.003 · Cited by 365 · see citing works

Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes

Jin, H., Kanthasamy, A., Ghosh, A., Anantharam, V., Kalyanaraman, B., & Kanthasamy, A. G. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.007 · Cited by 362 · see citing works

Receptor-Mediated Delivery of Magnetic Nanoparticles across the Blood–Brain Barrier

Qiao, R., Jia, Q., Hüwel, S., Xia, R., Liu, T., Gao, F., Galla, H., & Gao, M. (2012) · ACS Nano · doi:10.1021/nn300240p · Cited by 329 · see citing works

Assessment of PEG on polymeric particles surface, a key step in drug carrier translation

Rabanel, J., Hildgen, P., & Banquy, X. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.017 · Cited by 319 · see citing works

Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats

Fundaro', A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., & Gasco, M. R. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0695 · Cited by 317 · see citing works

Neurotoxicant-induced animal models of Parkinson?s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration

Uversky, V. N. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0937-z · Cited by 312 · see citing works

Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model

Md, S., Khan, R. A., Mustafa, G., Chuttani, K., Baboota, S., Sahni, J. K., & Ali, J. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.007 · Cited by 307 · see citing works

The hallmarks of P arkinson's disease

Antony, P. M. A., Diederich, N. J., Krüger, R., & Balling, R. (2013) · FEBS Journal · doi:10.1111/febs.12335 · Cited by 301 · see citing works

Antibodies against Polyethylene Glycol Produced in Animals by Immunization with Monomethoxy Polyethylene Glycol Modified Proteins

Richter, A. W., & Akerblom, E. B. (2009) · International Archives of Allergy and Applied Immunology · doi:10.1159/000233309 · Cited by 282 · see citing works

Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor

Prades, R., Guerrero, S., Araya, E., Molina-Pelayo, C., Salas‐Huenuleo, E., Zurita, E., Selva, J., Egea, G., López‐Iglesias, C., Teixidò, M., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.063 · Cited by 269 · see citing works

Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson's disease

Hu, K., Shi, Y., Jiang, W., Han, J., Huang, S., & Jiang, X. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.062 · Cited by 261 · see citing works

Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier Model

Wagner, S., Zensi, A., Wien, S., Tschickardt, S., Maier, W., Vogel, T., Worek, F., Pietrzik, C. U., Kreuter, J., & von Briesen, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032568 · Cited by 260 · see citing works

Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density

Vila, A., Gill, H., McCallion, O. N. M., & Alonso, M. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.04.026 · Cited by 249 · see citing works

Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration

Wen, Z., Yan, Z., Hu, K., Pang, Z., Cheng, X., Guo, L., Zhang, Q., Jiang, X., Fang, L., & Lai, R. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.022 · Cited by 241 · see citing works

Uptake and transport of high‐density lipoprotein (HDL) and HDL‐associated α‐tocopherol by an in vitro blood–brain barrier model

Balázs, Z., Panzenboeck, U., Hammer, A., Sovic, A., Quehenberger, O., Malle, E., & Sattler, W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02373.x · Cited by 239 · see citing works

Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery

Trapani, A., De Giglio, E., Cafagna, D., Denora, N., Agrimi, G., Cassano, T., Gaetani, S., Cuomo, V., & Trapani, G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.036 · Cited by 238 · see citing works

Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studies

Joshi, S. A., Chavhan, S. S., & Sawant, K. K. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.07.007 · Cited by 235 · see citing works

Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123

Tosi, G., Costantino, L., Rivasi, F., Ruozi, B., Leo, E., Vergoni, A. V., Tacchi, R., Bertolini, A., Vandelli, M. A., & Forni, F. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.022 · Cited by 233 · see citing works

Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer

Thomas, F. C., Taskar, K. S., Rudraraju, V., Goda, S., Thorsheim, H. R., Gaasch, J. A., Mittapalli, R. K., Palmieri, D., Steeg, P. S., Lockman, P. R., et al. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9964-5 · Cited by 227 · see citing works

Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art

Gastaldi, L., Battaglia, L., Peira, E., Chirio, D., Muntoni, E., Solazzi, I., Gallarate, M., & Dosio, F. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.05.004 · Cited by 223 · see citing works

Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems

Reis, C. P., Neufeld, R. J., Ribeiro, A. J., & Veiga, F. (2006) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2006.04.009 · Cited by 214 · see citing works

The genetics of Parkinson's syndromes: a critical review

Hardy, J., Lewis, P. A., Révész, T., Lees, A. J., & Paisán‐Ruiz, C. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.03.008 · Cited by 210 · see citing works

Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier

Costantino, L., Gandolfi, F., Tosi, G., Rivasi, F., Vandelli, M. A., & Forni, F. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.013 · Cited by 208 · see citing works

ABCA1 and Scavenger Receptor Class B, Type I, Are Modulators of Reverse Sterol Transport at an in Vitro Blood-Brain Barrier Constituted of Porcine Brain Capillary Endothelial Cells

Panzenboeck, U., Balázs, Z., Sovic, A., Hrzenjak, A., Levak‐Frank, S., Wintersperger, A., Malle, E., & Sattler, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207601200 · Cited by 196 · see citing works

Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: Influence of PEG coating on the particle size, drug release rate and phagocytic uptake

Fontana, G., Licciardi, M., Mansueto, S., Schillaci, D., & Giammona, G. (2001) · Biomaterials · doi:10.1016/s0142-9612(01)00030-8 · Cited by 192 · see citing works

Microbial Degradation of Poly(amino acid)s

Obst, M., & Steinbüchel, A. (2004) · Biomacromolecules · doi:10.1021/bm049949u · Cited by 191 · see citing works

A Nanomedicine Transports a Peptide Caspase-3 Inhibitor across the Blood–Brain Barrier and Provides Neuroprotection

Karataş, H., Aktaş, Y., Özdemir, Y., Bodur, E., Yemişçi, M., Caban-Toktas, S., Vural, A., Pınarbaşlı, O., Çapan, Y., Fernández-Megía, E., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4246-09.2009 · Cited by 187 · see citing works

Meta-analysis of Observational Studies

Greenwood, D. C. (2012) · Springer eBooks · doi:10.1007/978-94-007-3024-3_10 · Cited by 180 · see citing works

Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery

Sharma, S., Lohan, S., & Murthy, R. S. R. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.789051 · Cited by 163 · see citing works

Freezing of Gait in Parkinson’s Disease: Where Are We Now?

Heremans, E., Nieuwboer, A., & Vercruysse, S. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0350-7 · Cited by 159 · see citing works

Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles

Swarnakar, N. K., Jain, A., Singh, R. P., Godugu, C., Das, M., & Jain, S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.05.079 · Cited by 155 · see citing works

Particle size-dependent triggering of accelerated blood clearance phenomenon

Koide, H., Asai, T., Hatanaka, K., Urakami, T., Ishii, T., Kenjo, E., Nishihara, M., Yokoyama, M., Ishida, T., Kiwada, H., et al. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.06.004 · Cited by 148 · see citing works

Therapeutic prospects for Parkinson disease

Olanow, C. W., & Schapira, A. H. V. (2013) · Annals of Neurology · doi:10.1002/ana.24011 · Cited by 140 · see citing works

Oral Apomorphine Delivery from Solid Lipid Nanoparticles with Different Monostearate Emulsifiers: Pharmacokinetic and Behavioral Evaluations

Tsai, M.-J., Huang, Y.-B., Wu, P.-C., Fu, Y.-S., Kao, Y.-R., Fang, J.-Y., & Tsai, Y.-H. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22285 · Cited by 137 · see citing works

PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation

Muthu, M. S., Rawat, M. K., Mishra, A., & Singh, S. K. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2008.12.003 · Cited by 136 · see citing works

Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs

Suzuki, T., Ichihara, M., Hyodo, K., Yamamoto, E., Ishida, T., Kiwada, H., Ishihara, H., & Kikuchi, H. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.049 · Cited by 127 · see citing works

Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging

Fang, J., Wen, C.-J., Zhang, Z., Al-Suwayeh, & Yen, T. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29369 · Cited by 126 · see citing works

Surfactants, not size or zeta-potential influence blood–brain barrier passage of polymeric nanoparticles

Voigt, N., Henrich‐Noack, P., Kockentiedt, S., Hintz, W., Tomas, J., & Sabel, B. A. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.02.013 · Cited by 122 · see citing works

Toxicity of Polyalkylcyanoacrylate Nanoparticles I: Free Nanoparticles

Kante, B., Couvreur, P., Dubois-Krack, G., de Meester, C., Guiot, P., Roland, M., Mercier, M., & Speiseru, P. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600710716 · Cited by 121 · see citing works

Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study

Esposito, E., Mariani, P., Ravani, L., Contado, C., Volta, M., Bido, S., Drechsler, M., Mazzoni, S., Menegatti, E., Morari, M., et al. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.10.015 · Cited by 119 · see citing works

Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

Kalia, L., Brotchie, J., & Fox, S. H. (2013) · Movement Disorders · doi:10.1002/mds.25273 · Cited by 116 · see citing works

Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety

Nagpal, K., Singh, S. K., & Mishra, D. N. (2013) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2013.04.024 · Cited by 116 · see citing works

Epidemiology of Parkinson's disease

Liu, S., & Chan, P. (2016) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3969/cjcnn.v16i2.1351 · Cited by 115 · see citing works

Non-dopaminergic treatments in development for Parkinson's disease

Fox, S. H., Brotchie, J. M., & Lang, A. E. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70214-x · Cited by 112 · see citing works

Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson’s disease

Migliore, M. M., Ortiz, R., Dye, S., Campbell, R. B., Amiji, M. M., & Waszczak, B. L. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.05.019 · Cited by 107 · see citing works

Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent

Han, L., Li, J., Huang, S., Huang, R., Liu, S., Hu, X., Yi, P., Shan, D., Wang, X., Lei, H. C., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.005 · Cited by 107 · see citing works

Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?

Chaudhuri, К. R., Rizos, A., & Sethi, K. D. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-0981-5 · Cited by 104 · see citing works

A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier

Karkan, D., Pfeifer, C. G., Vitalis, T. Z., Arthur, G., Ujiie, M., Chen, Q., Tsai, S., Koliatis, G., Gabathuler, R., & Jefferies, W. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002469 · Cited by 103 · see citing works

In VitroandIn VivoStudy of Solid Lipid Nanoparticles Loaded with Superparamagnetic Iron Oxide

Peira, E., Marzola, P., Podio, V., Aime, S., Sbarbati, A., & Gasco, M. R. (2003) · Journal of drug targeting · doi:10.1080/1061186031000086108 · Cited by 102 · see citing works

Dynamics of Nanoparticle-Protein Corona Complex Formation: Analytical Results from Population Balance Equations

Sahneh, F. D., Scoglio, C., & Riviere, J. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064690 · Cited by 101 · see citing works

Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?

Costantino, L., & Boraschi, D. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.028 · Cited by 101 · see citing works

Neuroprotection in a 6‐hydroxydopamine‐lesioned Parkinson model using lactoferrin‐modified nanoparticles

Huang, R., Han, L., Li, J., Ren, F., Ke, W., Jiang, C., & Pei, Y. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1361 · Cited by 100 · see citing works

Parkinson's Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis

Jenner, P. G., Morris, H. R., Robbins, T. W., Goedert, M., Hardy, J., Ben‐Shlomo, Y., Bolam, J. P., Burn, D. J., Hindle, J. V., Brooks, D. J., et al. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130175 · Cited by 99 · see citing works

Purification of nanoparticle suspensions by a concentration/diafiltration process

Limayem, I., Charcosset, C., & Fessi, H. (2003) · Separation and Purification Technology · doi:10.1016/j.seppur.2003.10.002 · Cited by 99 · see citing works

Increasing the Effciency of Parkinson’s Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System

Gambaryan, P. Y., Кондрашева, И. Г., Severin, E. S., Guseva, A. A., & Kamensky, A. A. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.3.246 · Cited by 97 · see citing works

Emerging therapies for Parkinson's disease: From bench to bedside

Tarazi, F. I., Sahli, Z. T., Wolny, M., & Mousa, S. A. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.05.010 · Cited by 96 · see citing works

Novel surface modified polymer–lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation

Pardeshi, C. V., Belgamwar, V. S., Tekade, A. R., & Surana, S. J. (2013) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-013-4965-7 · Cited by 95 · see citing works

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

Garbayo, E., Ansorena, E., & Blanco‐Prieto, M. J. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.05.019 · Cited by 83 · see citing works

Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain

Pillay, S., Pillay, V., Choonara, Y. E., Naidoo, D., Khan, R. A., du Toit, L. C., Ndesendo, V. M. K., Modi, G., Danckwerts, M. P., & Iyuke, S. E. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.08.021 · Cited by 80 · see citing works

Scaling up feasibility of the production of solid lipid nanoparticles (SLN).

Gohla, S., & Dingler, A. (2001) · PubMed · Cited by 78 · see citing works

β-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain

Venishetty, V. K., Samala, R., Komuravelli, R., Kuncha, M., Sistla, R., & Diwan, P. V. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.08.004 · Cited by 73 · see citing works

Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism

Tiwari, M. N., Agarwal, S., Bhatnagar, P., Singhal, N. K., Tiwari, S. K., Kumar, P., Chauhan, L. K. S., Patel, D. K., Chaturvedi, R. K., Singh, M. P., et al. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.042 · Cited by 70 · see citing works

Development and Evaluation of Perfluorocarbon Nanobubbles for Apomorphine Delivery

Hwang, T., Lin, Y., Chi, C.-H., Huang, T., & Fang, J. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21687 · Cited by 69 · see citing works

Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson’s disease

Benazzouz, A., Mamad, O., Abedi, P., Bouali‐Benazzouz, R., & Chetrit, J. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00087 · Cited by 64 · see citing works

Production and characterization of novel chitosan nanoparticles for controlled release of rHu-Erythropoietin

Bulmer, C., Margaritis, A., & Xenocostas, A. (2012) · Biochemical Engineering Journal · doi:10.1016/j.bej.2012.07.007 · Cited by 63 · see citing works

Potential applications of nanotechnologies to Parkinson's disease therapy

Linazasoro, G. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.11.012 · Cited by 63 · see citing works

Studies on Biodegradable Polymeric Nanoparticles of Risperidone: In Vitro and In Vivo Evaluation

Muthu, M. S., & Singh, S. K. (2008) · Nanomedicine · doi:10.2217/17435889.3.3.305 · Cited by 59 · see citing works

Physicochemical characterization andin vivobioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug

Hsu, S.-H., Wen, C.-J., Al‐Suwayeh, S. A., Chang, H., Yen, T., & Fang, J. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/40/405101 · Cited by 58 · see citing works

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats

Yuan, W., Yang, X., Zheng, R., Cai, Y., Liao, M., & Liu, Z. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30463 · Cited by 56 · see citing works

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

Martínez‐Fong, D., Bannon, M. J., Trudeau, L., González-Barrios, J. A., Arango-Rodríguez, M. L., Hernández‐Chan, N. G., Reyes-Corona, D., Armendáriz‐Borunda, J., & Navarro-Quiroga, I. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.02.009 · Cited by 56 · see citing works

Advanced Parkinson's disease: Clinical characteristics and treatment (part 1)

Kulisevsky, J., Luquín, M. R., Arbelo, J. M., Burguera, J. A., Carrillo, F., Castro, A., Chacón, J., Ruiz, P., Lezcano, E., Mir, P., et al. (2013) · Neurología (English Edition) · doi:10.1016/j.nrleng.2013.05.002 · Cited by 55 · see citing works

Enfermedad de Parkinson avanzada. Características clínicas y tratamiento (parte I)

Kulisevsky, J., Luquín, M. R., Arbelo, J. M., Burguera, J. A., Carrillo, F., Castro, A., Chacón, J., Ruiz, P., Lezcano, E., Mir, P., et al. (2013) · Neurología · doi:10.1016/j.nrl.2013.05.001 · Cited by 55 · see citing works

Genetics and iron in the systems biology of Parkinson’s disease and some related disorders

Funke, C., Schneider, S. A., Berg, D., & Kell, D. B. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.11.015 · Cited by 54 · see citing works

Sensing surface PEGylation with microcantilevers

Backmann, N., Kappeler, N., Braun, T., Huber, F., Lang, H. P., Gerber, C., & Lim, R. Y. H. (2010) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.1.2 · Cited by 49 · see citing works

Influence of Surface-Modifying Surfactants on the Pharmacokinetic Behavior of 14C-Poly (Methylmethacrylate) Nanoparticles in Experimental Tumor Models

Lode, J., Fichtner, I., Kreuter, J., Berndt, A., Diederichs, J. E., & Reszka, R. C. (2001) · Pharmaceutical Research · doi:10.1023/a:1013094801351 · Cited by 47 · see citing works

Biopharmaceutical characterization of nanocrystalline solid dispersion of coenzyme Q10 prepared with cold wet-milling system

Onoue, S., Terasawa, N., Nakamura, T., Yuminoki, K., Hashimoto, N., & Yamada, S. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.12.013 · Cited by 43 · see citing works

Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II

Kulisevsky, J., Luquín, M. R., Arbelo, J. M., Burguera, J. A., Carrillo, F., Castro, A., Chacón, J., Ruiz, P., Lezcano, E., Mir, P., et al. (2013) · Neurología · doi:10.1016/j.nrl.2013.05.002 · Cited by 42 · see citing works

Nanoparticle Formulation Improves the Anticonvulsant Effect of Clonazepam on the Pentylenetetrazole-Induced Seizures: Behavior and Electroencephalogram

Leyva‐Gómez, G., González-Trujano, M. E., López-Ruiz, E., Couraud, P., Wekslerg, B., Romero, I. A., Miller, F., Delié, F., Allémann, É., & Quintanar‐Guerrero, D. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24044 · Cited by 41 · see citing works

Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases

Gabathuler, R. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709788680652 · Cited by 41 · see citing works

Cabergoline use and risk of fibrosis and insufficiency of cardiac valves

Vecchis, R. D., Esposito, C., & Ariano, C. (2013) · Herz · doi:10.1007/s00059-013-3816-0 · Cited by 39 · see citing works

Formulation and Characterization of Nanostructured Lipid Carrier of Ubiquinone (Coenzyme Q10)

Nanjwade, B. K., Kadam, V. T., & Manvi, F. V. (2013) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2013.1560 · Cited by 38 · see citing works

Lipid nanoparticles for brain targeting II. Technological characterization

Blasi, P., Schoubben, A., Romano, G. V., Giovagnoli, S., Michele, A. D., & Ricci, M. (2013) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.04.021 · Cited by 38 · see citing works

Continuous dopaminergic stimulation and novel formulations of dopamine agonists

Stocchi, F. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6024-y · Cited by 30 · see citing works

Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers for efficient brain targeting

Liu, K., Wen, C.-J., Yen, T., Sung, K. C., Ku, M.-C., Wang, J., & Fang, J. (2012) · Nanotechnology · doi:10.1088/0957-4484/23/9/095103 · Cited by 28 · see citing works

Effects of Levodopa loaded chitosan nanoparticles on cell viability and caspase-3 expression in PC12 neural like cells

Sadigh‐Eteghad, S., Talebi, M., Farhoudi, M., Mahmoudi, J., & Reyhani, B. (2013) · Neurosciences · doi:10.17712/1658-3183.2032 · Cited by 27 · see citing works

Fabrication, Modeling and Characterization of Multi-Crosslinked Methacrylate Copolymeric Nanoparticles for Oral Drug Delivery

Ngwuluka, N. C., Pillay, V., Choonara, Y. E., Modi, G., Naidoo, D., du Toit, L. C., Kumar, P., Ndesendo, V. M. K., & Khan, R. A. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12096194 · Cited by 21 · see citing works

Quinine, a selective gap junction blocker, decreases REM sleep in rats

Franco‐Pérez, J., & Paz, C. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.09.003 · Cited by 21 · see citing works

Parkin gene therapy

Mochizuki, H. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70012-4 · Cited by 10 · see citing works

Levodopa en el tratamiento de la enfermedad de Parkinson: mitos y realidades

Luquín, M. R., Ruiz, P., Martı́, M. J., Sebastián, A. R., Vela, L., Grandas, F., Bravo-Utrera, M., Burguera, J. A., Chacón, J., Arillo, V. M. C., et al. (2012) · Revista de Neurología · doi:10.33588/rn.5511.2012398 · Cited by 9 · see citing works

Continuing efforts to obtain continuous delivery of levodopa

Obeso, J. A., & Olanow, W. C. (2011) · Movement Disorders · doi:10.1002/mds.23996 · Cited by 8 · see citing works

Efficacy and Safety of Nasal Administration of “Na-no-L-DOPA” Based on PLGA Nanoparticles

Кондрашева, И. Г., Антипова, Т. А., Barsegyan, G. G., Gambaryan, P. Y., Guseva, A. A., & Kamensky, A. A. (2012) · Engineering · doi:10.4236/eng.2012.410b007 · Cited by 7 · see citing works

Dementia – The real problem for patients with Parkinson's disease

Klingelhoefer, L., & Reichmann, H. (2014) · Basal Ganglia · doi:10.1016/j.baga.2014.03.003 · Cited by 6 · see citing works

Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases

Chin-Chan, M., Navarro-Yepes, J., & Quintanilla‐Vega, B. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00124 · Cited by 712 · see citing works

Non-Ionic Surfactants for Stabilization of Polymeric Nanoparticles for Biomedical Uses

Cortés, H., Hernández‐Parra, H., Bernal-Chávez, S. A., Prado-Audelo, M. L. D., Caballero-Florán, I. H., Borbolla‐Jiménez, F. V., González‐Torres, M., Magaña, J. J., & Leyva‐Gómez, G. (2021) · Materials · doi:10.3390/ma14123197 · Cited by 304 · see citing works

Stimuli-responsive In situ gelling system for nose-to-brain drug delivery

Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Gupta, U. D., Kesharwani, P., Ravichandiran, V., Kumar, P., Naidu, V. G. M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.044 · Cited by 299 · see citing works

Nano carriers for drug transport across the blood–brain barrier

Li, X.-M., Tsibouklis, J., Weng, T., Zhang, B.-N., Yin, G.-Q., Feng, G.-Z., Cui, Y.-D., Savina, I., Mikhalovska, L., Sandeman, S., et al. (2017) · Journal of drug targeting (Print) · doi:10.1080/1061186x.2016.1184272 · Cited by 217 · see citing works

The protein corona and its effects on nanoparticle-based drug delivery systems

Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265 · see citing works

Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment

Bi, C., Wang, A., Chu, Y., Liu, S., Mu, H., Liu, W., Wu, Z., Sun, K., & Li, Y. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s120939 · Cited by 203 · see citing works

Nanocarriers for targeted drug delivery

Shah, A., Aftab, S., Nisar, J., Ashiq, M. N., & Iftikhar, F. J. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102426 · Cited by 193 · see citing works

Poly(trehalose) Nanoparticles Prevent Amyloid Aggregation and Suppress Polyglutamine Aggregation in a Huntington’s Disease Model Mouse

Debnath, K., Pradhan, N., Singh, B. K., Jana, N. R., & Jana, N. R. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06510 · Cited by 149 · see citing works

Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders

Md, S., Bhattamisra, S. K., Zeeshan, F., Shahzad, N., Mujtaba, M. A., Meka, V. S., Radhakrishnan, A. K., Kesharwani, P., Baboota, S., & Ali, J. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.09.022 · Cited by 138 · see citing works

Neurotheranostics as Personalized Medicines

Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124 · see citing works

PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

Cunha, A., Gaubert, A., Latxague, L., & Dehay, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071042 · Cited by 129 · see citing works

Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation

Sharifi-Rad, J., Rapposelli, S., Sestito, S., Herrera-Bravo, J., Arancibia-Diaz, A., Salazar, L. A., Yeskaliyeva, B., Beyatli, A., Leyva-Gómez, G., González-Contreras, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091515 · Cited by 125 · see citing works

Neuroprotective Effects of Curcumin in Neurodegenerative Diseases

Genchi, G., Lauria, G., Catalano, A. A., Carocci, A., & Sinicropi, M. S. (2024) · Foods · doi:10.3390/foods13111774 · Cited by 115 · see citing works

A Reevaluation of Chitosan-Decorated Nanoparticles to Cross the Blood-Brain Barrier

Cortés, H., Alcalá-Alcalá, S., Caballero-Florán, I. H., Bernal-Chávez, S. A., Ávalos‐Fuentes, A., González‐Torres, M., Carmen, M. G., Figueroa‐González, G., Reyes‐Hernández, O. D., Florán, B., et al. (2020) · Membranes · doi:10.3390/membranes10090212 · Cited by 108 · see citing works

Insights into Terminal Sterilization Processes of Nanoparticles for Biomedical Applications

Bernal-Chávez, S. A., Prado-Audelo, M. L. D., Caballero-Florán, I. H., Giraldo‐Gómez, D. M., Figueroa‐González, G., Reyes‐Hernández, O. D., Carmen, M. G., González‐Torres, M., Cortés, H., & Leyva‐Gómez, G. (2021) · Molecules · doi:10.3390/molecules26072068 · Cited by 92 · see citing works

In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery

Arısoy, S., SAYINER, Ö., Çomoğlu, T., Önal, D., Atalay, Ö., & Pehli̇vanoğlu, B. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2020.1740257 · Cited by 89 · see citing works

Chemically exfoliated WS2 nanosheets efficiently inhibit amyloid β-peptide aggregation and can be used for photothermal treatment of Alzheimer’s disease

Li, M. C., Zhao, A., Dong, K., Li, W., Ren, J., & Qu, X. (2015) · Nano Research · doi:10.1007/s12274-015-0821-z · Cited by 89 · see citing works

Functional single-walled carbon nanotubes ‘CAR’ for targeting dopamine delivery into the brain of parkinsonian mice

Guo, Q., You, H., Yang, X., Lin, B., Zhu, Z., Lu, Z., Li, X., Zhao, Y. S., Mao, L., Shen, S., et al. (2017) · Nanoscale · doi:10.1039/c7nr02682j · Cited by 70 · see citing works

Fullerenes: Historical background, novel biological activities versus possible health risks

Pesado-Gómez, C., Serrano‐García, J. S., Amaya‐Flórez, A., Pesado-Gómez, G., Soto‐Contreras, A., Morales‐Morales, D., & Colorado‐Peralta, R. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215550 · Cited by 61 · see citing works

The blood–brain barrier and beyond: Nano-based neuropharmacology and the role of extracellular matrix

Henrich‐Noack, P., Nikitovic, D., Neagu, M. T., Docea, A. O., Engin, A. B., Gelperina, S. E., Штильман, М. И., Mitsias, P. D., Tzanakakis, G. N., Gozes, I., et al. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.01.016 · Cited by 57 · see citing works

Nanomaterials for Parkinson disease: Recent progress

Ghazy, E., Rahdar, A., Barani, M., & Kyzas, G. Z. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129698 · Cited by 55 · see citing works

Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems

Rodríguez‐Nogales, C., Garbayo, E., Carmona‐Abellán, M., Luquín, M. R., & Blanco‐Prieto, M. J. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.11.009 · Cited by 54 · see citing works

Rapid and efficient crossing blood-brain barrier: Hydrophobic drug delivery system based on propionylated amylose helix nanoclusters

Gao, W., Liu, Y., Jing, G.-X., Li, K., Zhao, Y., Sha, B., Wang, Q., & Wu, D. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.045 · Cited by 54 · see citing works

Biodegradable Nanoparticles Loaded with Levodopa and Curcumin for Treatment of Parkinson’s Disease

Mogharbel, B. F., Cardoso, M. A., Irioda, A. C., Stricker, P. E. F., Slompo, R. C., Appel, J. M., de Oliveira, N. B., Perussolo, M. C., Saçaki, C. S., da Rosa, N. N., et al. (2022) · Molecules · doi:10.3390/molecules27092811 · Cited by 52 · see citing works

Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy

Kumar, P., Lakshmi, Y. S., & Kondapi, A. K. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2048-4 · Cited by 52 · see citing works

Emerging well-tailored nanoparticulate delivery system based on in situ regulation of the protein corona

Li, Z., Wang, Y., Zhu, J., Zhang, Y., Zhang, W., Zhou, M., Luo, C., Li, Z. J., Cai, B., Gui, S., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.007 · Cited by 50 · see citing works

Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach

Trompetero, A., Gordillo, A., del Pilar, M. C., Cristina, V., & Bustos, R. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170828133059 · Cited by 49 · see citing works

Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease

Li, A., Tyson, J., Patel, S. G., Patel, M., Katakam, S., Mao, X., & He, W. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.672594 · Cited by 46 · see citing works

Nanomedicine and drug delivery: A comprehensive review of applications and challenges

Singh, K., Singhal, S., Pahwa, S., Sethi, V. A., Sharma, S., Singh, P., Kale, R. D., Ali, S. W., & Sagadevan, S. (2024) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2024.101403 · Cited by 53 · see citing works

Targeted therapy of breast tumor by PLGA-based nanostructures: The versatile function in doxorubicin delivery

Dongsar, T. S., Dongsar, T. T., Molugulu, N., Annadurai, S., Wahab, S., Gupta, N., & Kesharwani, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116455 · Cited by 46 · see citing works

Alginate/magnetite hybrid beads for magnetically stimulated release of dopamine

Kondaveeti, S., Cornejo, D. R., & Petri, D. F. S. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.11.058 · Cited by 45 · see citing works

Twenty-Five Years of Nano-Bio-Materials: Have We Revolutionized Healthcare?

Pandit, A. S., & Zeugolis, D. I. (2016) · Nanomedicine · doi:10.2217/nnm.16.42 · Cited by 45 · see citing works

Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies

Karthivashan, G., Ganesan, P., Park, S., Lee, H., & Choi, D. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119704 · Cited by 45 · see citing works

Nanoneuromedicine for management of neurodegenerative disorder

Dwivedi, N., Shah, J., Mishra, V. K., Tambuwala, M. M., & Kesharwani, P. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.12.021 · Cited by 44 · see citing works

Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders

Smith, E. S., Porterfield, J. E., & Kannan, R. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.009 · Cited by 44 · see citing works

Tumor cellular membrane camouflaged liposomes as a non-invasive vehicle for genes: specific targeting toward homologous gliomas and traversing the blood–brain barrier

Zhao, Y., Shen, B., Li, X.-Z., Tong, M., Xue, P., Chen, R., Yao, Q., Chen, B., Xiao, J., & Xu, H. (2020) · Nanoscale · doi:10.1039/d0nr04212a · Cited by 37 · see citing works

Emerging Promise of Nanoparticle-Based Treatment for Parkinson’s disease

(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac106.71357151 · Cited by 37 · see citing works

Box-Behnken Design-Based Optimization and Evaluation of Lipid-Based Nano Drug Delivery System for Brain Targeting of Bromocriptine

Spandana, K. M. A., Angolkar, M., Rahamathulla, M., Thajudeen, K. Y., Ahmed, M. M., Farhana, S. A., Shivanandappa, T. B., Paramshetti, S., Osmani, R. A. M., & Natarajan, J. (2024) · Pharmaceuticals · doi:10.3390/ph17060720 · Cited by 36 · see citing works

Neuroprotective Potential and Chemical Profile of Alternatively Cultivated Ganoderma lucidum Basidiocarps

Ćilerdžić, J. L., Sofrenić, I. V., Tešević, V., Brčeski, I., Duletić-Laušević, S. N., Vukojević, J. B., & Stajić, M. M. (2018) · Chemistry & Biodiversity · doi:10.1002/cbdv.201800036 · Cited by 35 · see citing works

Delivery systems for theranostics in neurodegenerative diseases

Li, Y., Liu, R., Ji, W., Li, Y., Liu, L., & Zhang, X. (2018) · Nano Research · doi:10.1007/s12274-018-2067-z · Cited by 35 · see citing works

Recent Advances in Nanomaterials for Asthma Treatment

Xu, Z., Guo, X., Gu, Y., Zheng, H., Zhou, Z., Wang, X., Jiang, S., Wang, G., Xu, C., & Wang, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214427 · Cited by 31 · see citing works

In situ apolipoprotein E-enriched corona guides dihydroartemisinin-decorating nanoparticles towards LDLr-mediated tumor-homing chemotherapy

Li, Z., Zhu, J., Wang, Y., Zhou, M. L., Li, D., Zheng, S., Yin, L., Luo, C., Zhang, H., Zhong, L., et al. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.05.002 · Cited by 31 · see citing works

Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson’s disease

Duwa, R., Jeong, J., & Yook, S. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00521-3 · Cited by 30 · see citing works

Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization

Hernández‐Parra, H., Cortés, H., Ávalos‐Fuentes, J. A., Prado-Audelo, M. L. D., Florán, B., Leyva‐Gómez, G., Sharifi‐Rad, J., & Cho, W. C. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01612-5 · Cited by 27 · see citing works

Dopamine-loaded Poly (butyl cyanoacrylate) Nanoparticles Reverse Behavioral Deficits in Parkinson’s Animal Models

Jahansooz, F., Ebrahimi-Hosseinzadeh, B., Hatamian-Zarmi, A., Hadi, F., Hojjati, S. M. M., & Shahpasand, K. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0026 · Cited by 27 · see citing works

Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-ınduced Parkinson’s disease

Yeni, Y., Genç, S., Ertuğrul, M. S., Nadaroğlu, H., Gezer, A., Mendĭl, A. S., & Hacımüftüoğlu, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-69324-4 · Cited by 23 · see citing works

REMOVED: Mild traumatic brain injury exacerbates Parkinson's disease induced hemeoxygenase-2 expression and brain pathology: Neuroprotective effects of co-administration of TiO2 nanowired mesenchymal stem cells and cerebrolysin

Sharma, A., Muresanu, D. F., Nozari, A., Lafuente, J. V., Sahib, S., Tian, Z. R., Buzoianu, A. D., Patnaik, R., Wiklund, L., & Sharma, H. S. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.09.010 · Cited by 23 · see citing works

Development and application of nano-flavor-drug carriers in neurodegenerative diseases

Ji, W., Xiao, Z.-B., Liu, G., & Zhang, X. (2017) · Chinese Chemical Letters · doi:10.1016/j.cclet.2017.06.024 · Cited by 22 · see citing works

Studying CNS effects of Traditional Chinese Medicine using zebrafish models

Wang, D., Hu, G., Wang, J., Yan, D., Wang, M., Yang, L., Serikuly, N., Alpyshov, E. T., Demin, K. A., Galstyan, D. S., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113383 · Cited by 22 · see citing works

Designing nanoformulation for the nose‐to‐brain delivery in Parkinson's disease: Advancements and barrier

Kiran, P., Debnath, S. K., Neekhra, S., Pawar, V. S., Khan, A., Dias, F., Pallod, S., & Srivastava, R. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1768 · Cited by 21 · see citing works

Evolution of anti-parkinsonian activity of monoterpenoid (1 R ,2 R ,6 S )-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models

Вальдман, Е. А., Капица, И. Г., Иванова, Е. А., Voronina, T., Ardashov, O. V., Volcho, K. P., Хазанов, В. А., & Salakhutdinov, N. F. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.022 · Cited by 18 · see citing works

Nanomedicine against Alzheimer’s and Parkinson’s Disease

Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 19 · see citing works

Mathematical Optimisation of Magnetic Nanoparticle Diffusion in the Brain White Matter

Tian, Y., Yang, Y., Zhan, W., & Dini, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032534 · Cited by 18 · see citing works

Dual‐Functionalization Device for Therapy through Dopamine Release and Monitoring

Fabregat, G., Giménez, A., Díaz, A., Puiggalı́, J., & Alemán, C. (2018) · Macromolecular Bioscience · doi:10.1002/mabi.201800014 · Cited by 18 · see citing works

Evaluation of anti-cancer properties of pegylated ethosomal paclitaxel on human melanoma cell line SKMEL- 3

Eskolaky, E., Ardjmand, M., & Akbarzadeh, A. (2015) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v14i8.14 · Cited by 16 · see citing works

Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease

Moni, M. M. R., Begum, M. M., Uddin, M. S., & Ashraf, G. M. (2021) · Current Drug Metabolism · doi:10.2174/1389200222666210202110129 · Cited by 15 · see citing works

Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii

Lan, X., Qin, S., Liu, H., Guo, M., Zhang, Y., Jin, X., Duan, X., Sun, M., Liu, Z., Wang, W., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02373-z · Cited by 15 · see citing works

Biodegradable polymeric nanostructures: design and advances in oral drug delivery for neurodegenerative disorders

Ribeiro, A. M., Veiga, F., & Figueiras, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-47720-8.00003-1 · Cited by 15 · see citing works

Perspectives of nanobiotechnology and biomacromolecules in parkinson’s disease

Adam, H., Gopinath, S. C. B., Arshad, M. K. M., Adam, T., & Hashim, U. (2019) · Process Biochemistry · doi:10.1016/j.procbio.2019.07.019 · Cited by 15 · see citing works

Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders

Nguyen, T. T., Nguyen‐Thi, P., Nguyen, T. H. A., Ho, T.-T., An, T. N. M., Toi, V. V., & Giau, V. V. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00654-1 · Cited by 14 · see citing works

Advances in Alzheimer’s disease therapeutics: biochemistry, exploring bioactive compounds and novel approaches

Atoki, A. V., Aja, P. M., Ondari, E. N., & Shinkafi, T. S. (2023) · International Journal of Food Properties · doi:10.1080/10942912.2023.2243050 · Cited by 19 · see citing works

PLGA nanomedical consignation: A novel approach for the management of prostate cancer

Dongsar, T. S., Dongsar, T. T., Gupta, G., Alsayari, A., Wahab, S., & Kesharwani, P. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123808 · Cited by 14 · see citing works

New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors

Borbolla‐Jiménez, F. V., Prado-Audelo, M. L. D., Cisneros, B., Caballero-Florán, I. H., Leyva‐Gómez, G., & Magaña, J. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071018 · Cited by 13 · see citing works

Nanoparticles With Affinity for α-Synuclein Sequester α-Synuclein to Form Toxic Aggregates in Neurons With Endolysosomal Impairment

Jiang, P., Gan, M., Yen, S.-H. C., & Dickson, D. W. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.738535 · Cited by 13 · see citing works

Advancements in nose-to-brain drug targeting for Alzheimer’s disease: a review of nanocarriers and clinical insights

Komal, K., Ghosh, R., Sil, D., Sharma, R., Kumar, S., Pandey, P., & Kumar, M. (2025) · Inflammopharmacology · doi:10.1007/s10787-024-01636-3 · Cited by 15 · see citing works

Inorganic Nanoparticles and Their Strategies to Enhance Brain Drug Delivery

Toledo, E. G., Velasco-Aguirre, C., & Kogan, M. J. (2020) · Neuromethods · doi:10.1007/978-1-0716-0838-8_6 · Cited by 12 · see citing works

Progress, Opportunities, and Challenges of Magneto-Plasmonic Nanoparticles under Remote Magnetic and Light Stimulation for Brain-Tissue and Cellular Regeneration

Yuan, M., Harnett, M. C., Yan, T., Georgas, E., Qin, Y., Zhou, H.-C. “., & Wang, Y. (2022) · Nanomaterials · doi:10.3390/nano12132242 · Cited by 12 · see citing works

Nanotechnology in Parkinson’s Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes

Ali, I., Adil, M., Imran, M., Qureshi, S. A., Qureshi, S., Hasan, N., & Ahmad, F. J. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01799-8 · Cited by 11 · see citing works

Advanced strategies for enhancing the neuroprotective potential of curcumin: delivery systems and mechanistic insights in neurodegenerative disorders

Panda, P., Mohanty, S., Gouda, S. R., Baral, T. C., Mohanty, A., Nayak, J., & Mohapatra, R. (2025) · Nutritional Neuroscience · doi:10.1080/1028415x.2025.2472773 · Cited by 11 · see citing works

Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines

Rajpoot, K. (2020) · Current Drug Targets · doi:10.2174/1389450121666200106105633 · Cited by 11 · see citing works

Curcumin for parkinson´s disease: potential therapeutic effects, molecular mechanisms, and nanoformulations to enhance its efficacy

Cortés, H., Reyes‐Hernández, O. D., González‐Torres, M., Vizcaíno‐Dorado, P. A., Prado-Audelo, M. L. D., Alcalá-Alcalá, S., Sharifi‐Rad, J., Figueroa‐González, G., Carmen, M. G., Florán, B., et al. (2021) · Cellular and Molecular Biology · doi:10.14715/cmb/2021.67.1.15 · Cited by 10 · see citing works

Evaluation of the Transport and Binding of Dopamine-Loaded PLGA Nanoparticles for the Treatment of Parkinson’s Disease Using In Vitro Model Systems

Danz, K., Fleddermann, J., Koch, M., Fecioru, E., Maahs, L., Kinsinger, N., Krämer, J., Kraegeloh, A., & Wagner, S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050571 · Cited by 9 · see citing works

Effect of pramipexole alginate nanodispersion (PAND) on the transgenic Drosophila expressing human alpha synuclein in the brain

Siddique, Y. H., Naz, F., Khan, W., Jyoti, S., Singh, B. R., & Naqvi, A. H. (2017) · Journal of Applied Biomedicine · doi:10.1016/j.jab.2017.11.002 · Cited by 9 · see citing works

Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases

Nguyen‐Thi, P., Ho, T.-T., Nguyen, T. T., & Vo, G. V. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230707113405 · Cited by 8 · see citing works

Nano-Osmolyte Conjugation: Tailoring the Osmolyte-Protein Interactions at the Nanoscale

Sharma, H., Dar, T. A., Wijayasinghe, Y. S., Sahoo, D., & Poddar, N. K. (2023) · ACS Omega · doi:10.1021/acsomega.3c07248 · Cited by 8 · see citing works

Orally Administered Nanotherapeutics For Parkinson’s Disease: An Old Delivery System Yet More Acceptable

Aggarwal, N., Qamar, Z., Rehman, S., Baboota, S., & Ali, J. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200406072451 · Cited by 7 · see citing works

From the nose to the brain, nanomedicine drug delivery

Zeeshan, F., Mishra, D. K., & Kesharwani, P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820466-5.00008-9 · Cited by 7 · see citing works

Anti-Parkinson potential of hesperetin nanoparticles: in vivo and in silico investigations

Pasala, P. K., Prasanth, D., Rudrapal, M., Challa, R. R., Ahmad, S. F., Vallamkonda, B., & Ram Babu, R. (2024) · Natural Product Research · doi:10.1080/14786419.2024.2344740 · Cited by 6 · see citing works

Nanopartículas poliméricas de administración intranasal para la liberación de activos en el sistema nervioso central

García-Corvillo, M. D. P. (2016) · Ars Pharmaceutica (Internet) · doi:10.30827/ars.v57i1.4384 · Cited by 6 · see citing works

Nitroxide-containing amphiphilic polymers prepared by simplified electrochemically mediated ATRP as candidates for therapeutic antioxidants

Zaborniak, I., Pieńkowska, N., Chmielarz, P., Bartosz, G., Dziedzic, A., & Sadowska‐Bartosz, I. (2023) · Polymer · doi:10.1016/j.polymer.2023.125885 · Cited by 5 · see citing works

Nanotechnology and Parkinson’s disease

Mavridis, I. N., Meliou, M., Pyrgelis, E.-S., & Agapiou, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813667-6.00001-2 · Cited by 5 · see citing works

Curcumin-Loaded Nanoparticles in Neurodegenerative Diseases: Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis

PALANISAMY, S., Balasubramanian, A., Kanchana, M., Sisubalan, N., & Selvakesavan, R. K. (2025) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-80185-3_8 · Cited by 5 · see citing works

Nanopharmaceuticals

Quintanar‐Guerrero, D., Leyva‐Gómez, G., Magaña-Vergara, N. E., & Mendoza‐Muñoz, N. (2022) · doi:10.1002/9781119558026.ch4 · Cited by 5 · see citing works

Emerging anti-inflammatory nanosystems targeted to the brain

Mahanta, A. K., Gothwal, A., Chaulagain, B., Muolokwu, C. E., Tagoe, B., Lamsal, B., Belin, M. A. F., & Singh, J. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2552103 · Cited by 4 · see citing works

Emerging Nanotechnology for the Treatment and Diagnosis of Parkinson’s Disease (PD) and Alzheimer’s Disease (AD)

Kotha, S., Sriparna, M., Tyson, J., Li, A., He, W., & Mao, X. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-49744-5_5 · Cited by 4 · see citing works

Advances and challenges toward neural regenerative medicine

Dehghani, P., Jahed, V., & Zarrabi, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820223-4.00001-2 · Cited by 4 · see citing works

Therapeutic Implications of Nanopharmaceuticals in Skin Delivery

Mota, A. H., Santos-Rebelo, A., Almeida, A. J., & Reis, C. P. (2020) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-44925-4_6 · Cited by 4 · see citing works

Current treads of targeted nanoparticulate carriers for the treatment of Alzheimer’s disease

Gheidari, D., & Bayat, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00005-8 · Cited by 3 · see citing works

Recent Advances in Nanocarrier-Based Brain-Targeted Drug Delivery for Effective Treatment of Central Nervous System Disorders

Sarwal, A., Singh, G., Prasad, P., Sharma, S., & Ali, W. (2020) · Springer eBooks · doi:10.1007/978-3-030-41858-8_9 · Cited by 2 · see citing works

Application of nano- and micro-particle-based approaches for selected bronchodilators in management of asthma

Singh, S., Aparna, Sharma, N., Gupta, J., Kyada, A., Nathiya, D., Behl, T., Gupta, S., Anwer, M. K., Gulati, M., et al. (2024) · 3 Biotech · doi:10.1007/s13205-024-04051-1 · Cited by 1 · see citing works

Gene therapy in neurodegenerative disorders

Ali, H. T., Sula, I., Elrefaey, A., Ashour, Y., Eltaras, M. M., Mohamed, H., & Meshref, M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00036-1 · Cited by 1 · see citing works

Expanding the Arsenal of Nanocarriers Against Parkinson Disease: Success so Far Roads Ahead

Devi, N., Dhiman, S., Dora, C. P., Singh, T. G., & Awasthi, A. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03234-0 · Cited by 1 · see citing works

Brain-targeting lipid nanoparticles of nicotinamide mononucleotide: preparation, optimization, and characterization

Lin, Y., Zhao, F., Wang, J., Ping, S., Wu, K., Chen, Y., Zheng, X., & Xu, H. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1759167 · Cited by 1 · see citing works

Polymeric-Based Theranostic Nanocarriers of Neuroprotective Drugs: Development, Imaging, and Bioanalysis

Szczepanowicz, K., Procner, M., Szczęch, M., Łopuszyńska, N., Jantas, D., Regulska, M., Leśkiewicz, M., Jasiński, K., Stachurski, K., Szyk‐Warszyńska, L., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00170 · Cited by 1 · see citing works

Nanoparticular Drug Delivery Systems in the Treatment Central Nervous System Diseases: Review

Arısoy, S., SAYINER, Ö., & Çomoğlu, T. (2017) · Turkiye Klinikleri Journal of Pharmacy Sciences · doi:10.5336/pharmsci.2017-56331

Nasal delivery nanoparticles

Obulesu, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819882-7.00008-8

Insights into Sub-20 nm Nanocarriers (3-helix Micelles) at the Molecular and Cellular Level

Jung, B. T. (2020) · eScholarship (California Digital Library)

Additional file 1 of Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii

Lan, X., Qin, S., Liu, H., Guo, M., Zhang, Y., Jin, X., Duan, X., Sun, M., Liu, Z., Wang, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26699807

Integrative Nanomedicine Approaches and Secondary Metabolites in Neurodegenerative Diseases

Çakar, B., Çadirci, C., & Kilic, K. D. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-1365-8.ch013

Nanoparticles for drug delivery in Parkinson’s disease

Baskin, J., Jeon, J. E., & Lewis, S. J. G. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10291-x · Cited by 67 · see citing works

Recent Advancement in the Nanoparticles Mediated Therapeutics of Parkinson’s Disease

Chaturvedi, V. K., Singh, P., & singh, M. (2021) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681087726121010014 · Cited by 8 · see citing works

Theoretical and applied concepts of nanocarriers for the treatment of Parkinson's diseases

Bhosale, A., Paul, G., Mazahir, F., & Yadav, A. K. (2022) · OpenNano · doi:10.1016/j.onano.2022.100111 · Cited by 15 · see citing works

Nanomedicine to Overcome Current Parkinson’s Treatment Liabilities: A Systematic Review

Hawthorne, G. H., Bernuci, M. P., Bortolanza, M., Tumas, V., Issy, A. C., & Bel, E. A. D. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9663-z · Cited by 24 · see citing works

Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease

Moni, M. M. R., Begum, M. M., Uddin, M. S., & Ashraf, G. M. (2021) · Current Drug Metabolism · doi:10.2174/1389200222666210202110129 · Cited by 15 · see citing works